<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Posts | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>Posts</span>
        <span>2024-05-21</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://blogs.rstudio.com/tensorflow/posts/2024-05-21-keras3">Introducing Keras 3 for R</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/blogs-rstudio-com-tensorflow-posts-2024-05-21-keras3/">
    
    
    
    
    
      
    
    We are thrilled to introduce {keras3}, the next version of the Keras R package. {keras3} is a ground-up rebuild of {keras}, maintaining the beloved features of the original while refining and simplifying the API based on valuable insights gathered over the past few &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38769795/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Safety and tolerability of radiotherapy in combination with systemic targeted therapies for treatment of hepatocellular carcinoma: a narrative review</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38769795-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Existing data suggests that combination RT and targeted therapy given the risk of severe adverse events including hepatotoxicity and GI toxicity. There is an urgent need for future studies specifically examining the impact of combination therapy in HCC patients to guide clinical decision-making in the evolving landscape of immune- and targeted &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38769902/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38769902-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The Scale for the Assessment and Rating of Ataxia (SARA) is widely used for assessing the severity and progression of genetic cerebellar ataxias. SARA is now considered a primary end point in several ataxia treatment trials, but its underlying composite item measurement model has not yet been tested. This work aimed to evaluate the composite properties of SARA and its items using item response theory (IRT) and to demonstrate its applicability across even ultra-rare genetic ataxias. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38769948/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Activity of afatinib in patients with NSCLC harboring novel uncommon &lt;em&gt;EGFR&lt;/em&gt; mutations with or without co-mutations: a case report</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38769948-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent first-line standard of care in unresectable EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). However, 10-20% of patients with EGFRm+ NSCLC have uncommon EGFR variants, defined as mutations other than L858R substitutions or exon 19 deletions. NSCLC harboring uncommon EGFR mutations may demonstrate lower sensitivity to targeted agents than NSCLC with L858R or exon 19 deletion &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38770115/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Similarity of Seroma Rate at the Medial Thigh following Free Flap Harvesting or Medial Thigh Lift: A Systematic Review and Meta-analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38770115-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Despite the growing use of autologous breast reconstruction with medial thigh-based free flaps, such as transverse upper gracilis (TMG) or profunda artery perforator (PAP) flaps, these procedures are infrequently performed on patients with obesity. This systematic review and meta-analysis aimed to compare the frequency of seroma occurrence, a common complication after medial thigh flap surgery. Comparison was performed between TMG and PAP flaps, as well as medial thigh lifts (MTL), a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38770165/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Is neoadjuvant chemotherapy followed by surgery the appropriate treatment for esophagogastric signet ring cell carcinomas? A systematic review and meta-analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38770165-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The current meta-analysis could not demonstrate beneficial effects of nCTX for SRCC patients. Histopathological response to and survival benefits of non-taxane-based nCTX seem to be lower in comparison to non-SRC esophagogastric cancer. However, certainty of evidence is low due to the scarcity of high-quality trials. Further research is necessary to determine optimal treatment for SRCC &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38770539/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">A photoaging smartphone application to promote sun safety behaviors among youth in late childhood and adolescence</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38770539-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The findings of this cross-sectional study suggest that a photoaging smartphone application may serve as a useful tool to promote sun safety behaviors from a young &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38770848/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Toward a causal model of curiosity and creativity</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38770848-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    We extend Ivancovsky et al.&rsquo;s finding on the association between curiosity and creativity by proposing a sequential causal model assuming that (a) curiosity determines the motivation to seek information and that (b) creativity constitutes a capacity to act on that motivation. This framework assumes that both high levels of curiosity and creativity are necessary for information-seeking &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38770889/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240521183000&amp;v=2.18.0.post9&#43;e462414">Audio Interview: The Current State of Avian Influenza</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38770889-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240521183000-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38770914/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Closing the loop between environment, brain and mental health: how far we might go in real-life assessments?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38770914-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    PURPOSE OF REVIEW: Environmental factors such as climate, urbanicity, and exposure to nature are becoming increasingly important influencers of mental health. Incorporating data gathered from real-life contexts holds promise to substantially enhance laboratory experiments by providing a more comprehensive understanding of everyday behaviors in natural environments. We provide an up-to-date review of current technological and methodological developments in mental health assessments, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38771375/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Heritable pulmonary arterial hypertension</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38771375-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Heritable pulmonary arterial hypertension (PAH) can be triggered by at least 18 genes. The most frequently altered gene is the bone morphogenetic protein receptor 2 (BMPR2). Further genes from the same pathway are also well known PAH-causing genes. Genetic testing can aid to confirm differential diagnoses such as a pulmonary veno-occlusive disease. It also enables the testing of healthy family members. In addition to the PAH patient population particularly served by genetic testing, this &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38771544/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Diagnostic accuracy of Afirma Gene Expression Classifier, Afirma Gene Sequencing Classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38771544-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: We showed that in patients with ITN, TSv3 has the best molecular diagnostic performance, followed by TSv2, GSC, and GEC. For rule-out malignancy, GSC, and for rule-in, TSV2 is superior to other &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pypi.org/project/label-studio/1.12.1/">1.12.1</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/pypi-org-project-label-studio-1-12-1/">
    
    
    
    
    
      
    
    Label Studio annotation &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfmBrybyb">ğŸ”»å†…å¡”å°¼äºšèƒ¡ï¼šâ€œæŒ‡æ§æˆ‘åœ¨åŠ æ²™çš„ç½ªè¡Œå°±åƒæŒ‡æ§ä¹”æ²»Â·å¸ƒä»€çŠ¯æœ‰9/11äº‹ä»¶çš„ç½ªè¡Œä¸€æ ·ã€‚â€ğŸ”»â€¦â€¦ğŸ”»ğŸ‡ºğŸ‡¸ï¼š[å“†å•¦Aæ¢¦å®³æ€•] ğŸ”»å¤ªæ•¢è®²äº†ï¼Œä½ è¿˜çœŸæ˜¯ä»€ä¹ˆè¯éƒ½æ•¢è®²...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofmbrybyb/">
    
    
    
    
    
      
    
    ğŸ”»å†…å¡”å°¼äºšèƒ¡ï¼šâ€œæŒ‡æ§æˆ‘åœ¨åŠ æ²™çš„ç½ªè¡Œå°±åƒæŒ‡æ§ä¹”æ²»Â·å¸ƒä»€çŠ¯æœ‰9/11äº‹ä»¶çš„ç½ªè¡Œä¸€æ ·ã€‚â€<!-- raw HTML omitted -->ğŸ”»â€¦â€¦<!-- raw HTML omitted -->ğŸ”»ğŸ‡ºğŸ‡¸ï¼š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->ğŸ”»å¤ªæ•¢è®²äº†ï¼Œä½ è¿˜çœŸæ˜¯ä»€ä¹ˆè¯éƒ½æ•¢è®²å•Šã€‚<!-- raw HTML omitted -->ğŸ”»via ABC news<!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B8%AD%E6%96%B9%E8%A6%81%E6%B1%82%E4%BB%A5%E8%89%B2%E5%88%97%E7%AB%8B%E5%8D%B3%E5%81%9C%E6%AD%A2%E5%86%9B%E4%BA%8B%E8%BF%9B%E6%94%BB%E6%8B%89%E6%B3%95%23&amp;amp;extparam=%23%E4%B8%AD%E6%96%B9%E8%A6%81%25">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B8%AD%E6%96%B9%E8%A6%81%E6%B1%82%E4%BB%A5%E8%89%B2%E5%88%97%E7%AB%8B%E5%8D%B3%E5%81%9C%E6%AD%A2%E5%86%9B%E4%BA%8B%E8%BF%9B%E6%94%BB%E6%8B%89%E6%B3%95%23&amp;amp;extparam=%23%E4%B8%AD%E6%96%B9%E8%A6%81%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfmG0lt3E">ğŸ”»è¿˜è®°å¾—æ²™å°¼å¢å…‹å—ï¼Ÿï¼ˆå›¾1ï¼‰ğŸ”»æ²™å°¼å¢å…‹çš„çˆ¶äº²å°¼è¥¿å§†-å¢å…‹ï¼ˆNissim Loukï¼‰ä¸Šå‘¨äº”å¯¹ã€Šçº½çº¦é‚®æŠ¥ã€‹è¯´ï¼šâ€œæˆ‘ä»¬ç°åœ¨æ‹¥æœ‰çš„è¿™å…·é—ä½“æ˜¯å®Œæ•´è€Œç¾ä¸½çš„ï¼Œçœ‹èµ·æ¥å¥¹è¿˜æ´»...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofmg0lt3e/">
    
    
    
    
    
      
    
    ğŸ”»è¿˜è®°å¾—æ²™å°¼å¢å…‹å—ï¼Ÿï¼ˆå›¾1ï¼‰<!-- raw HTML omitted -->ğŸ”»æ²™å°¼å¢å…‹çš„çˆ¶äº²å°¼è¥¿å§†-å¢å…‹ï¼ˆNissim Loukï¼‰ä¸Šå‘¨äº”å¯¹ã€Šçº½çº¦é‚®æŠ¥ã€‹è¯´ï¼šâ€œæˆ‘ä»¬ç°åœ¨æ‹¥æœ‰çš„è¿™å…·é—ä½“æ˜¯å®Œæ•´è€Œç¾ä¸½çš„ï¼Œçœ‹èµ·æ¥å¥¹è¿˜æ´»ç€ã€‚æˆ‘è®¤ä¸ºå¥¹æ›¾åœ¨ä¸€ä¸ªéå¸¸éå¸¸å¯’å†·çš„éš§é“é‡Œ&hellip;&hellip;è¿™å°±æ˜¯ä¸ºä»€ä¹ˆå°¸ä½“å®Œæ•´è€Œç¾ä¸½ï¼Œçš®è‚¤çš„é¢œè‰²ä¾ç„¶å¦‚æ•…ï¼Œä½ ä¾ç„¶èƒ½çœ‹åˆ°çº¹èº«ï¼Œè¿™å¤ªç¥å¥‡äº†ã€‚â€ï¼ˆè§†é¢‘2ï¼Œå›¾3ï¼‰<!-- raw HTML omitted -->ğŸ”»è¿™æ˜¯æ²™å°¼å¢å…‹çš„çˆ¶æ¯ä¸ä»€ç©†åˆ©-åšå¡”èµ«å¯¹è¯çš„ä¸€éƒ¨åˆ†ã€‚<!-- raw HTML omitted -->ğŸ”»â€¦â€¦æ€»æ„Ÿè§‰æœ‰å“ªé‡Œä¸å¯¹ï¼Œè®©æˆ‘ä»¬æ¥æ‹ä¸€æ‹ï¼š<!-- raw HTML omitted -->ğŸ”»é¦–å…ˆï¼Œè‡ªå»å¹´ 10 æœˆ 7 æ—¥ä»¥æ¥ï¼Œå¥¹ä¸€ç›´å‡ºç°åœ¨ä»¥è‰²åˆ—çš„å®£ä¼ ä¸­ï¼Œä»¥è‰²åˆ—çš„æ€»ç»Ÿåœ¨å»å¹´ 10 æœˆ 30 æ—¥è‡³ 31 æ—¥è¯´â€œå¥¹çš„å°¸ ä½“è¢«å‘ç°è¢«æ–© é¦–â€ï¼ˆå›¾4-5ï¼Œä»¥è‰²åˆ—i24æ–°é—»é¢‘é“ï¼‰ã€‚<!-- raw HTML omitted -->ğŸ”»å½“æ—¶ï¼Œä»–ä»¬å£°ç§°ä»–ä»¬å‘ç°äº†å¥¹çš„å¤´éª¨ï¼Œæ‰€ä»¥ä»–ä»¬è®¤ä¸ºå¥¹å·²ç»æ­»äº†ï¼Œä»–ä»¬ä½¿ç”¨â€œæ–© é¦–â€çš„å®£ä¼ ã€‚<!-- raw HTML omitted -->ğŸ”»ç„¶è€Œï¼Œå¥¹çš„é—ä½“å·ç§°æœ€è¿‘åœ¨æ‹‰æ³•è¢«å‘ç°å¹¶é€å›æ¥äº†ï¼Œä½ çŒœæ€ä¹ˆç€ï¼Ÿå¥¹çš„é—ä½“å®Œå¥½æ— æŸï¼Œâ€œçœ‹èµ·æ¥å¥¹è¿˜æ´»ç€â€ï¼Œæ­£å¦‚å¥¹çˆ¶æ¯æ‰€æ‰¿è®¤çš„é‚£æ ·ã€‚<!-- raw HTML omitted -->ğŸ”»é‚£å»å¹´ä»¥è‰²åˆ—æ€»ç»Ÿå£°ç§°å‘ç°çš„æ˜¯ä»€ä¹ˆï¼Ÿæ€»ç»Ÿå“â€¦â€¦<!-- raw HTML omitted -->ğŸ”»â€¦â€¦æœ‰æ²¡æœ‰ç†Ÿæ‚‰æ³•åŒ»å·¥ä½œçš„ç½‘å‹ï¼Œæ„Ÿè§‰çœŸçš„å¯¹ä¸ä¸Šã€‚&lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ofmglzyut">ğŸ”»å¤šç®¡ç«ç®­ç‚®è¢­å‡»åˆ«æ´›æˆˆç½—å¤«å¡ã€‚ğŸ”»via VK åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofmglzyut/">
    
    
    
    
    
      
    
    ğŸ”»å¤šç®¡ç«ç®­ç‚®è¢­å‡»åˆ«æ´›æˆˆç½—å¤«å¡ã€‚<!-- raw HTML omitted -->ğŸ”»via VK <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/EJE2NGdJlx08f2hELbeE010412">https://f.video.weibocdn.com/o0/EJE2NGdJlx08f2hELbeE010412</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfmlVcCYR">ğŸ”»ç¾è”ç¤¾çš„ä¸€ç¯‡æŠ¥é“ã€‚ğŸ”»å›¾8æ˜¯2013 å¹´ 8 æœˆ 25 æ—¥ï¼Œåœ¨åŠ åˆ©ç¦å°¼äºšå·ä¼˜èƒœç¾åœ°å›½å®¶å…¬å›­é™„è¿‘çš„å¤§ç«æœŸé—´ï¼Œå›šçŠ¯æ¶ˆé˜²å‘˜æ²¿ç€ 120 å·é«˜é€Ÿå…¬è·¯è¡Œèµ°ã€‚ğŸ”»å›¾9ä¸­ï¼Œä¸€äº›å…¨...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofmlvccyr/">
    
    
    
    
    
      
    
    ğŸ”»ç¾è”ç¤¾çš„ä¸€ç¯‡æŠ¥é“ã€‚<!-- raw HTML omitted -->ğŸ”»å›¾8æ˜¯2013 å¹´ 8 æœˆ 25 æ—¥ï¼Œåœ¨åŠ åˆ©ç¦å°¼äºšå·ä¼˜èƒœç¾åœ°å›½å®¶å…¬å›­é™„è¿‘çš„å¤§ç«æœŸé—´ï¼Œå›šçŠ¯æ¶ˆé˜²å‘˜æ²¿ç€ 120 å·é«˜é€Ÿå…¬è·¯è¡Œèµ°ã€‚<!-- raw HTML omitted -->ğŸ”»å›¾9ä¸­ï¼Œä¸€äº›å…¨å¥³æ€§å›šçŠ¯é˜Ÿä¼è¢«æ´¾å»æ¸…ç†å†…åè¾¾å·çš„é‡ç«çƒ­ç‚¹ï¼Œå¥¹ä»¬åªæ¥å—è¿‡è¯¾å ‚åŸ¹è®­ï¼Œå¥¹ä»¬åœ¨é—·çƒ§çš„ä½™çƒ¬ä¸Šè·³äº†ä¸€æ®µâ€œçƒ­è„šèˆâ€ï¼Œå› ä¸ºå¥¹ä»¬çš„è€æ¿å¤§å–Šâ€œå›åˆ°é‚£é‡Œâ€ï¼Œä¸€åå¥³æ€§å›šçŠ¯å·¥äººè¢«çƒ§æ¯çš„é´å­è¢«ç”¨èƒ¶å¸¦ç²˜åœ¨ä¸€èµ·ï¼Œè€Œå…¶ä»–äººåˆ™ç—›è‹¦åœ°å“­æ³£ï¼Œå› ä¸ºå¥¹ä»¬çš„è¢œå­åœ¨åœ°ä¸ŠèåŒ–äº†ä¹ä¸ªå°æ—¶ï¼Œæ¯å°æ—¶æŠ¥é…¬çº¦1ç¾å…ƒã€‚<!-- raw HTML omitted -->ğŸ”»ä¸¤å¤©åï¼Œè¿™äº›å¦‡å¥³æœ€ç»ˆè¢«é€å¾€å¤–é¢çš„ä¸€å®¶åŒ»é™¢ï¼ŒåŒ»ç”Ÿä»å¥¹ä»¬çš„è„šåº•åˆ‡ä¸‹æ­»çš®ï¼Œè¿™äº›è„šè¢«äºŒåº¦çƒ§ä¼¤ã€‚å› ä¸ºå¥¹ä»¬æ˜¯å›šçŠ¯ï¼Œæ‰€ä»¥å¥¹ä»¬è¢«å‰¥å¤ºäº†æ­¢ç—›è¯ã€‚<!-- raw HTML omitted -->ğŸ”»æ ¹æ®ç¾å›½å®ªæ³•ç¬¬ 13 æ¡ä¿®æ­£æ¡ˆï¼Œç¾å›½æœ‰å®é™…çš„å¥´éš¶åŠ³åŠ¨ï¼Œè¯¥ä¿®æ­£æ¡ˆè§„å®šâ€œå¥´éš¶åˆ¶å’Œéè‡ªæ„¿å¥´å½¹ä½œä¸ºå¯¹çŠ¯ç½ªçš„æƒ©ç½šæ˜¯åˆæ³•çš„â€ï¼Œè¶…è¿‡80ä¸‡å›šçŠ¯ä¸ºâ€œæ¯å°æ—¶å‡ ç¾åˆ†æˆ–æ ¹æœ¬æ²¡æœ‰â€å·¥ä½œã€‚<!-- raw HTML omitted -->ğŸ”»ç¾å›½ä¹Ÿæ˜¯è¿„ä»Šä¸ºæ­¢ä¸–ç•Œä¸Šç›‘ç¦ç‡æœ€é«˜çš„å›½å®¶ã€‚<!-- raw HTML omitted -->ğŸ”»ç¾å›½æ˜¯ä¸–ç•Œä¸Šä»…æœ‰çš„ä¸¤ä¸ªæ²¡æœ‰æ‰¹å‡†1930å¹´ã€Šå¼ºè¿«åŠ³åŠ¨å…¬çº¦ã€‹çš„å›½å®¶ä¹‹ä¸€ï¼Œå¦ä¸€ä¸ªæ²¡æœ‰æ‰¹å‡†å®ƒçš„å›½å®¶æ˜¯é˜¿å¯Œæ±—ã€‚æ€»è€Œè¨€ä¹‹ï¼Œç¾å›½åªæ‰¹å‡†äº†17é¡¹å›½é™…åŠ³å·¥ç»„ç»‡ï¼ˆILOï¼‰å…¬çº¦ï¼ˆå›¾13ï¼‰ï¼Œè¿™åŸºæœ¬ä¸Šæ˜¯ä¸–ç•Œä¸Šæœ€ä½çš„ï¼Œ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfmnnCMmy">ğŸ”»è‰ã€‚ğŸ”»ä¸‰å“¥å¤šå¥‡å¿—ã€‚ğŸ”»via Abhiram K. J. åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofmnncmmy/">
    
    
    
    
    
      
    
    ğŸ”»è‰ã€‚<!-- raw HTML omitted -->ğŸ”»ä¸‰å“¥å¤šå¥‡å¿—ã€‚<!-- raw HTML omitted -->ğŸ”»via Abhiram K. J. <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/ovdq2I8Tlx08f2iQvG">https://f.video.weibocdn.com/o0/ovdq2I8Tlx08f2iQvG</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfmoKrdSg">ğŸ”»ç¾è”ç¤¾ï¼šç¾è”ç¤¾è®°è€…ä¸€ç›´åœ¨ä»¥è‰²åˆ—å—éƒ¨æ‹æ‘„åŠ æ²™å…¨æ™¯ï¼Œä½†æ˜¯å‘¨äºŒï¼Œä»¥è‰²åˆ—å®˜å‘˜çªè¢­äº†è¿™é‡Œï¼Œæ²¡æ”¶äº†æ‰£æŠ¼äº†å±äºç¾è”ç¤¾çš„ç›¸æœºå’Œå¹¿æ’­è®¾å¤‡ï¼Œå¹¶æ’¤ä¸‹äº†å®å†µç›´æ’­ã€‚ğŸ”»è¿™æ¬¡...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofmokrdsg/">
    
    
    
    
    
      
    
    ğŸ”»ç¾è”ç¤¾ï¼šç¾è”ç¤¾è®°è€…ä¸€ç›´åœ¨ä»¥è‰²åˆ—å—éƒ¨æ‹æ‘„åŠ æ²™å…¨æ™¯ï¼Œä½†æ˜¯å‘¨äºŒï¼Œä»¥è‰²åˆ—å®˜å‘˜çªè¢­äº†è¿™é‡Œï¼Œæ²¡æ”¶äº†æ‰£æŠ¼äº†å±äºç¾è”ç¤¾çš„ç›¸æœºå’Œå¹¿æ’­è®¾å¤‡ï¼Œå¹¶æ’¤ä¸‹äº†å®å†µç›´æ’­ã€‚<!-- raw HTML omitted -->ğŸ”»è¿™æ¬¡çªè¢­æ˜¯åœ¨å‘¨å››å£å¤´å‘½ä»¤åœæ­¢ç›´æ’­ä¹‹åè¿›è¡Œçš„ï¼Œç¾è”ç¤¾æ‹’ç»è¿™æ ·åšã€‚<!-- raw HTML omitted -->ğŸ”»ä»¥è‰²åˆ—åå¯¹å…šé¢†è¢–äºšä¼Šå°”-æ‹‰çš®å¾·ç§°æ­¤ä¸¾ä¸ºâ€œç–¯ç‹‚ä¹‹ä¸¾â€ã€‚<!-- raw HTML omitted -->ğŸ”»â€œè¿™ä¸æ˜¯åŠå²›ç”µè§†å°ã€‚è¿™æ˜¯ä¸€å®¶ç¾å›½æ–°é—»æœºæ„ï¼Œâ€ä»–è¯´ã€‚â€œè¿™ä¸ªæ”¿åºœçš„è¡Œä¸ºå°±å¥½åƒå®ƒå†³å®šä¸æƒœä¸€åˆ‡ä»£ä»·ç¡®ä¿ä»¥è‰²åˆ—åœ¨å…¨ä¸–ç•Œé­åˆ°å”¾å¼ƒã€‚â€<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax2.sinaimg.cn/large/639b1bfbly1hpxjql85egj20or0kwjwr.jpg%22">https://tvax2.sinaimg.cn/large/639b1bfbly1hpxjql85egj20or0kwjwr.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfmoZr0uj">è¯´æ˜¯æŸåœ°â€œéŸ³ä¹èŠ‚â€//@è·¯é¥çŸ¥é©¬åŠ›Emmm:è¿™å•¥å•Š - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»è‰ã€‚ğŸ”»ä¸‰å“¥å¤šå¥‡å¿—ã€‚ğŸ”»via Abhiram K. J. åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofmozr0uj/">
    
    
    
    
    
      
    
    è¯´æ˜¯æŸåœ°â€œéŸ³ä¹èŠ‚â€//<!-- raw HTML omitted -->@è·¯é¥çŸ¥é©¬åŠ›Emmm<!-- raw HTML omitted -->:è¿™å•¥å•Š<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»è‰ã€‚<!-- raw HTML omitted -->ğŸ”»ä¸‰å“¥å¤šå¥‡å¿—ã€‚<!-- raw HTML omitted -->ğŸ”»via Abhiram K. J. <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;br &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfmvBzwdU">ğŸ”»è‰ åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofmvbzwdu/">
    
    
    
    
    
      
    
    ğŸ”»è‰ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/ZFLKaoC4lx08f2keMIdG01041200aNGu0E010.mp4?label=mp4_720p">https://f.video.weibocdn.com/o0/ZFLKaoC4lx08f2keMIdG01041200aNGu0E010.mp4?label=mp4_720p</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ofn5cCp6Y">ğŸ”»è¿™æ˜¯ä¼Šæœ—æ€»ç»ŸåŠå…¬å®¤ä¸»ä»»å´æ‹‰å§†Â·è«è¾›Â·åŸƒæ–¯è¿ˆåˆ©å¯¹ä¼Šæœ—æ€»ç»Ÿç›´å‡æœºå æœºäº‹ä»¶æè¿°çš„é‡è¦å’Œæ–°ç»†èŠ‚ï¼Œä»–å½“æ—¶åœ¨ç¬¬ä¸‰æ¶ç›´å‡æœºä¸Šã€‚ğŸ”»é‡‡è®¿ç”± IRIBNEWS æ’­å‡ºï¼ˆä¼Šæœ—å¹¿æ’­...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofn5ccp6y/">
    
    
    
    
    
      
    
    ğŸ”»è¿™æ˜¯ä¼Šæœ—æ€»ç»ŸåŠå…¬å®¤ä¸»ä»»å´æ‹‰å§†Â·è«è¾›Â·åŸƒæ–¯è¿ˆåˆ©å¯¹ä¼Šæœ—æ€»ç»Ÿç›´å‡æœºå æœºäº‹ä»¶æè¿°çš„é‡è¦å’Œæ–°ç»†èŠ‚ï¼Œä»–å½“æ—¶åœ¨ç¬¬ä¸‰æ¶ç›´å‡æœºä¸Šã€‚<!-- raw HTML omitted -->ğŸ”»é‡‡è®¿ç”± IRIBNEWS æ’­å‡ºï¼ˆä¼Šæœ—å¹¿æ’­ç”µè§†å°ï¼Œæ˜¯ä¼Šæœ—ç¬¬ä¸€å®¶å¹¿æ’­ç”µå°ï¼Œæˆç«‹äº1938å¹´ï¼Œæ˜¯ä¼Šæœ—å”¯ä¸€è¦†ç›–å…¨å›½çš„å¹¿æ’­ç”µè§†åª’ä½“ï¼‰ã€‚<!-- raw HTML omitted -->ğŸ”»å´æ‹‰å§†Â·è«è¾›Â·åŸƒæ–¯è¿ˆåˆ©è¯´ï¼š<!-- raw HTML omitted -->ğŸ”¹æˆ‘ä»¬åœ¨å½“åœ°ä¸¾è¡Œäº†ä¸€ä¸ªå¤šå°æ—¶çš„æ–°å¤–äº¤ä¼šè®®ï¼Œä¸­åˆè¿›è¡Œäº†ç¥ˆç¥·ï¼Œå½“åœ°æ°‘ä¼—ä¹Ÿæœ‰è¦æ±‚ã€‚é˜¿äºšå›¾æ‹‰è±è¥¿å‡ºç°åœ¨è¯¥åœ°åŒºçš„ç¥ˆç¥·å¤§å…å¹¶å›ç­”äº†äººä»¬çš„è¯·æ±‚ã€‚<!-- raw HTML omitted -->ğŸ”¹ç»è¿‡ä¸­åˆçš„ç¥ˆç¥·å’Œä¼šä¼—ï¼Œä¸‹åˆä¸€ç‚¹å·¦å³ï¼Œé£å¾€å¤§ä¸é‡Œå£«çš„èˆªç­åœ¨å¤©æ°”æ™´æœ—ã€æ²¡æœ‰ä»»ä½•ç‰¹æ®Šå¤©æ°”ç°è±¡çš„æƒ…å†µä¸‹èµ·é£ã€‚<!-- raw HTML omitted -->ğŸ”¹åœ¨ Songun é“œçŸ¿åŒºé™„è¿‘çš„å±±è°·ä¸­ç§»åŠ¨45åˆ†é’Ÿåï¼Œæˆ‘çœ‹åˆ°ä¸€ç‰‡äº‘å—åƒå¤©ç©ºä¸­çš„æ¡Œå­ä¸€æ ·è”“å»¶ï¼Œåœ°é¢ä¸Šæœ‰é›¾ï¼Œä½†æˆ‘ä»¬ä¹˜åç›´å‡æœºå‰è¿›çš„ç©ºä¸­æ²¡æœ‰é›¾ã€‚ä¸è¿‡ï¼Œåœ¨ä¸€ä¸ªå°çš„å¯†é›†åŒºåŸŸï¼Œæ‚¬å´–ä¸Šæ–¹æœ‰ä¸€å°ç‰‡äº‘ã€‚ä»é«˜åº¦ä¸Šçœ‹ï¼Œè¿™ç‰‡äº‘ä¸æˆ‘ä»¬çš„é£è¡Œé«˜åº¦ç›¸åŒï¼Œç”šè‡³æˆ‘ä»¬æ¯”äº‘è¿˜è¦ä½ä¸€ç‚¹ã€‚<!-- raw HTML omitted -->ğŸ”¹åœ¨é‚£é‡Œï¼Œæ‹…ä»»æ€»ç»Ÿç›´å‡æœº &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ofn6gor6p">ä½ è¦è¯´911æœ‰é˜´è°‹ï¼Œé‚£æˆ‘å¯å°±çœŸä¿¡äº†å—·ï¼Ÿ - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»å†…å¡”å°¼äºšèƒ¡ï¼šâ€œæŒ‡æ§æˆ‘åœ¨åŠ æ²™çš„ç½ªè¡Œå°±åƒæŒ‡æ§ä¹”æ²»Â·å¸ƒä»€çŠ¯æœ‰9/11äº‹ä»¶çš„ç½ªè¡Œä¸€æ ·ã€‚â€ğŸ”»...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofn6gor6p/">
    
    
    
    
    
      
    
    ä½ è¦è¯´911æœ‰é˜´è°‹ï¼Œé‚£æˆ‘å¯å°±çœŸä¿¡äº†å—·ï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»å†…å¡”å°¼äºšèƒ¡ï¼šâ€œæŒ‡æ§æˆ‘åœ¨åŠ æ²™çš„ç½ªè¡Œå°±åƒæŒ‡æ§ä¹”æ²»Â·å¸ƒä»€çŠ¯æœ‰9/11äº‹ä»¶çš„ç½ªè¡Œä¸€æ ·ã€‚â€<!-- raw HTML omitted -->ğŸ”»â€¦â€¦<!-- raw HTML omitted -->ğŸ”»ğŸ‡ºğŸ‡¸ï¼š<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->ğŸ”»å¤ªæ•¢è®²äº†ï¼Œä½ è¿˜çœŸæ˜¯ä»€ä¹ˆè¯éƒ½æ•¢è®²å•Šã€‚<!-- raw HTML omitted -->ğŸ”»via ABC news<!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B8%AD%E6%96%B9%E8%A6%81%E6%B1%82%E4%BB%A5%E8%89%B2%E5%88%97%E7%AB%8B%E5%8D%B3%E5%258">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B8%AD%E6%96%B9%E8%A6%81%E6%B1%82%E4%BB%A5%E8%89%B2%E5%88%97%E7%AB%8B%E5%8D%B3%E5%8</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OfloLwwv4">ä¹…ä¿å²ç»ªé‡ŒVia.ä¹ƒæœ¨å‚46 X [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-21</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oflolwwv4/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->Via.ä¹ƒæœ¨å‚46 X <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38764777/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Targeting thalamocortical circuits for closed-loop stimulation in Lennox-Gastaut syndrome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38764777-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    This paper outlines the therapeutic rationale and neurosurgical targeting technique for bilateral, closed-loop, thalamocortical stimulation in Lennox-Gastaut syndrome, a severe form of childhood-onset epilepsy. Thalamic stimulation can be an effective treatment for Lennox-Gastaut syndrome, but complete seizure control is rarely achieved. Outcomes may be improved by stimulating areas beyond the thalamus, including cortex, but the optimal targets are unknown. We aimed to identify a cortical &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38765202/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38765202-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The deviations revealed the necessity of systematic trainings with appropriate feedback before the start of clinical trials in radiation oncology and the constant monitoring of protocol compliance throw-out the &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38765263/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Evolution of peripheral nerve changes in early multiple sclerosis-a longitudinal MR neurography study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38765263-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Peripheral nerve involvement in MS appears at initial diagnosis and continues to evolve within 1 year follow-up with individual dynamics. Quantitative MRN provides non-invasive biomarkers to detect and monitor peripheral nerve changes in &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38765578/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Steroid-Resistant Nephrotic Syndrome due to &lt;em&gt;NPHS2&lt;/em&gt; Variants Is Not Associated With Posttransplant Recurrence</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38765578-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: In this large cohort, the risk of patients with causative variants in the NPHS2 gene to develop NS recurrence after kidney transplantation was extremely low. This is coherent with the pathophysiology of intrinsic slit-diaphragm disease. These data are reassuring and should be considered when counselling patients, making living kidney donation, whether related or not, a safe &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38765898/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Management of Patients with Breast Biopsy under Anti-Coagulation or Anti-Platelet Therapy: Results of a Survey of German Experts</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38765898-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Breast biopsies for patients on ASA or prophylactic heparin are deemed safe and part of standard clinical practice. However, despite available feasibility studies, conducting breast biopsies on ACT medications such as DOACs or phenprocoumon appears feasible only for a minority of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767063/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Hypoparathyroidism update</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767063-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    PURPOSE OF REVIEW: Since the release of the 2022 Second International Workshop Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines, updates and advances are now available in the cause, complications, and treatment of adult chronic hypoparathyroidism (hypoPTH). This review aims to highlight these new findings and implications to patient &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767091/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Successful Aging and Subjective Aging: Toward a Framework to Research a Neglected Connection</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767091-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Research related to subjective aging, which describes how individuals perceive, interpret and evaluate their own aging, has substantially grown in the past two decades. Evidence from longitudinal studies shows that subjective aging predicts health, quality of life, and functioning in later life. However, the existing literature on successful aging has mostly neglected the role of subjective aging. This paper proposes an extended framework of successful aging linking subjective aging &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767162/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Association between self-reported functional capacity measures and postoperative myocardial injury in patients undergoing noncardiac surgeries</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767162-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767162/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Association between self-reported functional capacity measures and postoperative myocardial injury in patients undergoing noncardiac surgeries</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767162-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767179/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Skin fragility and wound management in Ehlers- Danlos Syndrome: a report by the Ehlers Danlos Syndrome society skin working group</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767179-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The Ehlers-Danlos Syndromes (EDS) are a heterogenous group of heritable connective tissue disorders, characterised by joint hypermobility, skin hyperextensibility and generalised tissue fragility. In all types of EDS skin wound healing is impaired to a variable degree. Additional support through wound management plans may help to improve these outcomes, however, there is paucity of evidence regarding clinical management of skin fragility and wounds in EDS. This paper aims to review &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767179/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Skin fragility and wound management in Ehlers- Danlos Syndrome: a report by the Ehlers Danlos Syndrome society skin working group</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767179-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The Ehlers-Danlos Syndromes (EDS) are a heterogenous group of heritable connective tissue disorders, characterised by joint hypermobility, skin hyperextensibility and generalised tissue fragility. In all types of EDS skin wound healing is impaired to a variable degree. Additional support through wound management plans may help to improve these outcomes, however, there is paucity of evidence regarding clinical management of skin fragility and wounds in EDS. This paper aims to review &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767226/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Procedural and clinical outcomes of patients undergoing a TAVI in TAVI procedure: Rationale and design of the multicentre, prospective, observational ReTAVI registry</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767226-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The registry will collect pre-, peri-, postoperative and 12-months data on patients undergoing repeated TAVI procedures with THVs for failure of the index THV and determine VARC-3-defined efficacy and safety at 30 days and functional outcome at 12 months. The registry will expand existing data sets and identify patient characteristics/indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767226/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Procedural and clinical outcomes of patients undergoing a TAVI in TAVI procedure: Rationale and design of the multicentre, prospective, observational ReTAVI registry</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767226-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The registry will collect pre-, peri-, postoperative and 12-months data on patients undergoing repeated TAVI procedures with THVs for failure of the index THV and determine VARC-3-defined efficacy and safety at 30 days and functional outcome at 12 months. The registry will expand existing data sets and identify patient characteristics/indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767237/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240520180847&amp;v=2.18.0.post9&#43;e462414">Beyond Diagnostics - Removing Race from Lung-Function Test Interpretation</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767237-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240520180847-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767237/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240521183000&amp;v=2.18.0.post9&#43;e462414">Beyond Diagnostics - Removing Race from Lung-Function Test Interpretation</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767237-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240521183000-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767244/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240520180847&amp;v=2.18.0.post9&#43;e462414">A Modular Communicative Leadless Pacing-Defibrillator System</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767244-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240520180847-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The leadless pacemaker in wireless communication with a subcutaneous ICD exceeded performance goals for freedom from major complications related to the leadless pacemaker, for communication between the leadless pacemaker and subcutaneous ICD, and for the percentage of patients with a pacing threshold up to 2.0 V at a 0.4-msec pulse width at 6 months. (Funded by Boston Scientific; MODULAR ATP ClinicalTrials.gov &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767244/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240521183000&amp;v=2.18.0.post9&#43;e462414">A Modular Communicative Leadless Pacing-Defibrillator System</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767244-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240521183000-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The leadless pacemaker in wireless communication with a subcutaneous ICD exceeded performance goals for freedom from major complications related to the leadless pacemaker, for communication between the leadless pacemaker and subcutaneous ICD, and for the percentage of patients with a pacing threshold up to 2.0 V at a 0.4-msec pulse width at 6 months. (Funded by Boston Scientific; MODULAR ATP ClinicalTrials.gov &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767248/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240520180847&amp;v=2.18.0.post9&#43;e462414">Early Diagnosis and Treatment of COPD and Asthma - A Randomized, Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767248-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240520180847-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In this trial in which a strategy was used to identify adults in the community with undiagnosed asthma or COPD, those who received pulmonologist-directed treatment had less subsequent health care utilization for respiratory illness than those who received usual care. (Funded by Canadian Institutes of Health Research; UCAP ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767248/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240521183000&amp;v=2.18.0.post9&#43;e462414">Early Diagnosis and Treatment of COPD and Asthma - A Randomized, Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767248-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240521183000-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In this trial in which a strategy was used to identify adults in the community with undiagnosed asthma or COPD, those who received pulmonologist-directed treatment had less subsequent health care utilization for respiratory illness than those who received usual care. (Funded by Canadian Institutes of Health Research; UCAP ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767252/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240520180847&amp;v=2.18.0.post9&#43;e462414">Implications of Race Adjustment in Lung-Function Equations</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767252-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240520180847-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The use of race-based and race-neutral equations generated similarly accurate predictions of respiratory outcomes but assigned different disease classifications, occupational eligibility, and disability compensation for millions of persons, with effects diverging according to race. (Funded by the National Heart Lung and Blood Institute and the National Institute of Environmental Health &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767252/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240521183000&amp;v=2.18.0.post9&#43;e462414">Implications of Race Adjustment in Lung-Function Equations</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767252-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240521183000-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: The use of race-based and race-neutral equations generated similarly accurate predictions of respiratory outcomes but assigned different disease classifications, occupational eligibility, and disability compensation for millions of persons, with effects diverging according to race. (Funded by the National Heart Lung and Blood Institute and the National Institute of Environmental Health &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767511/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240520180849&amp;v=2.18.0.post9&#43;e462414">Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767511-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240520180849-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Hereditary angioedema (HAE) due to C1 inhibitor protein (C1-INH) deficiency was recently shown to be associated with increased risk of venous thromboembolism (VTE). This is the first national family study of HAE with the aim to determine the familial risk of VTE. The Swedish Multi-Generation Register was linked to the Swedish National Patient Register during the period 1964-2018. Only HAE patients with a validated diagnosis were included in the study and were linked to their family &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767511/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240521183001&amp;v=2.18.0.post9&#43;e462414">Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767511-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240521183001-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Hereditary angioedema (HAE) due to C1 inhibitor protein (C1-INH) deficiency was recently shown to be associated with increased risk of venous thromboembolism (VTE). This is the first national family study of HAE with the aim to determine the familial risk of VTE. The Swedish Multi-Generation Register was linked to the Swedish National Patient Register during the period 1964-2018. Only HAE patients with a validated diagnosis were included in the study and were linked to their family &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767614/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240520180847&amp;v=2.18.0.post9&#43;e462414">Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767614-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240520180847-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with COPD and type 2 inflammation as indicated by elevated blood eosinophil counts, dupilumab was associated with fewer exacerbations and better lung function than placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; NOTUS ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767614/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240521183000&amp;v=2.18.0.post9&#43;e462414">Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767614-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240521183000-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In patients with COPD and type 2 inflammation as indicated by elevated blood eosinophil counts, dupilumab was associated with fewer exacerbations and better lung function than placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; NOTUS ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767697/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240520180926&amp;v=2.18.0.post9&#43;e462414">Long-term outcome of patients with MÃ©niÃ¨re&#39;s disease following cochlear implantation: a comprehensive outcome study with validated assessment tools</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767697-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240520180926-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: CI has positive effects on all areas examined in our cohort. However, discrimination of speech at low sound pressure levels remained problematic postoperatively. In patients suffering from MD, the prioritized treatment goals include not only improved hearing but also the rehabilitation of vertigo and tinnitus, as well as the enhancement of QoL. Validated instruments are useful screening &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38767697/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Long-term outcome of patients with MÃ©niÃ¨re&#39;s disease following cochlear implantation: a comprehensive outcome study with validated assessment tools</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38767697-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: CI has positive effects on all areas examined in our cohort. However, discrimination of speech at low sound pressure levels remained problematic postoperatively. In patients suffering from MD, the prioritized treatment goals include not only improved hearing but also the rehabilitation of vertigo and tinnitus, as well as the enhancement of QoL. Validated instruments are useful screening &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38768337/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240521183001&amp;v=2.18.0.post9&#43;e462414">EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38768337-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240521183001-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Estimating progression-free survival (PFS) and overall survival (OS) superiority during clinical trials of multiple myeloma (MM) has become increasingly challenging as novel therapeutics have improved patient outcomes. Thus, it is imperative to identify earlier endpoint surrogates that are predictive of long-term clinical benefit to expedite development of more effective therapies. Minimal residual disease (MRD)-negativity is a common intermediate endpoint that has shown prognostic value &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38768337/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38768337-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Estimating progression-free survival (PFS) and overall survival (OS) superiority during clinical trials of multiple myeloma (MM) has become increasingly challenging as novel therapeutics have improved patient outcomes. Thus, it is imperative to identify earlier endpoint surrogates that are predictive of long-term clinical benefit to expedite development of more effective therapies. Minimal residual disease (MRD)-negativity is a common intermediate endpoint that has shown prognostic value &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38768421/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38768421-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Melanoma has long been a difficult malignancy to treat with low response rates to standard chemotherapies. In recent years, the use of immune checkpoint inhibitors have demonstrated promising results, paving the way for the use of the rapidly developing novel immune targeting therapies. In this review, we look beyond immune checkpoint inhibitor treatments and summarize several emerging treatment strategies for melanoma, including neoantigen vaccines, conventional antibody drug-conjugates, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38768763/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Cardiomyocyte-specific RXFP1 overexpression protects against pressure overload-induced cardiac dysfunction independently of Relaxin</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38768763-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Heart failure (HF) prevalence is rising due to reduced early mortality and demographic change. Relaxin (RLN) mediates protective effects in the cardiovascular system through Relaxin-receptor 1 (RXFP1). Cardiac overexpression of RXFP1 with additional RLN supplementation attenuated HF in the pressure-overload transverse aortic constriction (TAC) model. Here, we hypothesized that robust transgenic RXFP1 overexpression in cardiomyocytes (CM) protects from TAC-induced HF even in the absence of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38769164/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTRâ€‘targeting peptide [&lt;sup&gt;18&lt;/sup&gt;F]SiTATE</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38769164-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: SSTR-RADS 1.0 represents a highly reproducible and consistent framework system for stratifying SSTR-targeted PET/CT scans, even using the novel SSTR-ligand [^(18)F]SiTATE. Some inter-reader variability was observed regarding the evaluation of uptake intensity prior to PRRT as well as compartment scoring of lymph nodes, indicating that those categories require special attention during further clinical validation and might be refined in a future SSTR-RADS version &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38769332/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">Cytomegalovirus drives VÎ´1&lt;sup&gt;&#43;&lt;/sup&gt; Î³Î´ T cell expansion and clonality in common variable immunodeficiency</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38769332-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The function and phenotype of Î³Î´ T cells in the context of common variable immunodeficiency (CVID) has not been explored. CVID is a primary immunodeficiency disorder characterized by impaired antibody responses resulting in increased susceptibility to infections. Î³Î´ T cells are a subset of unconventional T cells that play crucial roles in host defence against infections. In this study, we aim to determine the roles and functions of Î³Î´ T cells in CVID. We observe a higher frequency of VÎ´1^(+) &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/38769371/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240521183404&amp;v=2.18.0.post9&#43;e462414">A large and diverse brain organoid dataset of 1,400 cross-laboratory images of 64 trackable brain organoids</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-38769371-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240521183404-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Brain organoids represent a useful tool for modeling of neurodevelopmental disorders and can recapitulate brain volume alterations such as microcephaly. To monitor organoid growth, brightfield microscopy images are frequently used and evaluated manually which is time-consuming and prone to observer-bias. Recent software applications for organoid evaluation address this issue using classical or AI-based methods. These pipelines have distinct strengths and weaknesses that are not evident &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/Of7ckoBnH">åˆæ˜¯å¤©æ°”å¤§å¥½çš„ä¸€å¤©ï¼Œè€Œæ¹¾åŒºå¤å¤©æµ·è¾¹æ²¡æœ‰é›¾çš„å‘¨æœ«å¾ˆå°‘è§ã€‚åˆ°San Gregorioèµ°äº†2 milesã€‚å› ä¸ºå¤©æ°”å¥½ï¼Œè¿™ç‰‡å¹³æ—¶äººè¿¹ç½•è‡³çš„æµ·æ»©ä»Šå¤©ä¹Ÿæœ‰ä¸€äº›æ¸¸äººã€‚ ç¾å›½Â·Pescadero ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-of7ckobnh/">
    
    
    
    
    
      
    
    åˆæ˜¯å¤©æ°”å¤§å¥½çš„ä¸€å¤©ï¼Œè€Œæ¹¾åŒºå¤å¤©æµ·è¾¹æ²¡æœ‰é›¾çš„å‘¨æœ«å¾ˆå°‘è§ã€‚åˆ°San Gregorioèµ°äº†2 milesã€‚å› ä¸ºå¤©æ°”å¥½ï¼Œè¿™ç‰‡å¹³æ—¶äººè¿¹ç½•è‡³çš„æµ·æ»©ä»Šå¤©ä¹Ÿæœ‰ä¸€äº›æ¸¸äººã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ç¾å›½Â·Pescadero Beach<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/4">https://tvax3.sinaimg.cn/large/4</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/Of80AmqGB">San Gregorioæµ·æ»©ã€‚ å­é™µåœ¨å¬æ­Œçš„å¾®åšè§†é¢‘</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-of80amqgb/">
    
    
    
    
    
      
    
    San Gregorioæµ·æ»©ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å­é™µåœ¨å¬æ­Œçš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/kQjosMfvlx08eZQR6pEk01041200hajv0E010.mp4?lab">https://f.video.weibocdn.com/o0/kQjosMfvlx08eZQR6pEk01041200hajv0E010.mp4?lab</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/Of8BAiYep">ä¸€ä¸ªæœ‹å‹åŠå¼€ç©ç¬‘åœ°é€æˆ‘äº†ä¸€æœ¬ä¹¦ï¼Œæ²¡æƒ³åˆ°è¯»èµ·æ¥è§‰å¾—è¿˜æŒºæœ‰æ”¶è·çš„ï¼Œå«stop walking on eggshellsã€‚å…¶å®æˆ‘è§‰å¾—å®ƒå¾ˆé€‚åˆå¾ˆå¤šä¸€ä»£ä¸œäºšç§»æ°‘å®¶é•¿è¯»ç»™å­©å­ï¼Œä¹Ÿç®—æ˜¯åŠ æ·±...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-of8baiyep/">
    
    
    
    
    
      
    
    ä¸€ä¸ªæœ‹å‹åŠå¼€ç©ç¬‘åœ°é€æˆ‘äº†ä¸€æœ¬ä¹¦ï¼Œæ²¡æƒ³åˆ°è¯»èµ·æ¥è§‰å¾—è¿˜æŒºæœ‰æ”¶è·çš„ï¼Œå«stop walking on eggshellsã€‚å…¶å®æˆ‘è§‰å¾—å®ƒå¾ˆé€‚åˆå¾ˆå¤šä¸€ä»£ä¸œäºšç§»æ°‘å®¶é•¿è¯»ç»™å­©å­ï¼Œä¹Ÿç®—æ˜¯åŠ æ·±è‡ªæˆ‘è®¤çŸ¥çš„è¿‡ç¨‹ã€‚è¿™æœ¬ä¹¦è®²äº†åœ¨ç”Ÿæ´»ä¸­æˆ‘ä»¬æ€»ä¼šé‡åˆ°éå¸¸éš¾ä»¥ç›¸å¤„çš„äººï¼Œå…¶ä¸­ä¸å°‘äººæœ‰BPDï¼ˆè¾¹ç¼˜æ€§äººæ ¼éšœç¢ï¼‰ï¼Œéå¸¸æ˜“æ¿€æ˜“æ€’ã€‚å¦‚æœè¿™äº›äººæ°æ˜¯å®¶äººæˆ–è€…äº²å¯†æœ‹å‹æˆ–è€…ä¸Šå¸ï¼Œé‚£ä¹ˆå¤„ç†è¿™ç§äººé™…å…³ç³»åˆ™å˜å¾—å¾ˆå…·æœ‰æŒ‘æˆ˜æ€§ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->è¿™æœ¬ä¹¦æä¾›çš„æ–¹æ³•ç¬¬ä¸€æ˜¯set healthy boundariesï¼ˆæœ‰åº•çº¿ï¼‰ï¼Œç¬¬äºŒæ˜¯å‹å–„è€Œæ¸…æ™°åœ°äº¤æµã€‚æ¯”å¦‚ä½“ç°åœ¨é‡åˆ°æŒ‘è¡…æˆ–äº‰åµï¼ˆfightï¼‰æ—¶å€™ä¸å‘æ€’ï¼Œä¸ç«‹å³ååº”ä»¥ä½¿å¯¹æ–¹æ›´æ¿€æ€’ï¼Œä½†ç­‰å¯¹æ–¹å¹³é™ä¸‹æ¥åè¦å‘å¯¹æ–¹è¡¨ç¤ºè¿™æ ·åšæ˜¯ä¸å¯¹çš„ï¼Œç„¶åæ¸…æ™°åœ°å‘Šè¯‰å¯¹æ–¹å“ªé‡Œåšå¾—ä¸å¯¹è®©è‡ªå·±åº•çº¿è¢«ç¢°è§¦ã€‚å…¶å®è¿™ä¹Ÿæ˜¯ä¸€äº›å—è¿‡æ•™è‚²çš„ç¾å›½å®¶é•¿æ•™è‚²å­©å­çš„æ–¹å¼ï¼Œå°±æ˜¯â€œcall out bad behaviour &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1655755343/OfcbyxF0z">ä¸€å¡Œç³Šæ¶‚çš„ä¸€å¤©ã€‚æ‰“çƒŠäº†çœ‹åˆ°ä¸€æ ·ä¸€å¡Œç³Šæ¶‚å´è¿˜èƒ½è‡ªå·²å‘ç”µçš„äººï¼Œå¾ˆç¾¡æ…•ğŸ˜†åƒç›æ ¼ä¸½ç‰¹ç ¸è¿‡çš„åºŸå¢Ÿé‡Œé•¿å‡ºäº†é›Œé›„æ›¼é™€ç½—èŠ±ï¼Œç”¨æ¥è®©èœœèœ‚é•‡ç—›ï¼Œè®©è´è¶å‘ç¥ç»ç—…ğŸ¦‹ [å›¾ç‰‡...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1655755343-ofcbyxf0z/">
    
    
    
    
    
      
    
    ä¸€å¡Œç³Šæ¶‚çš„ä¸€å¤©ã€‚æ‰“çƒŠäº†çœ‹åˆ°ä¸€æ ·ä¸€å¡Œç³Šæ¶‚å´è¿˜èƒ½è‡ªå·²å‘ç”µçš„äººï¼Œå¾ˆç¾¡æ…•ğŸ˜†åƒç›æ ¼ä¸½ç‰¹ç ¸è¿‡çš„åºŸå¢Ÿé‡Œé•¿å‡ºäº†é›Œé›„æ›¼é™€ç½—èŠ±ï¼Œç”¨æ¥è®©èœœèœ‚é•‡ç—›ï¼Œè®©è´è¶å‘ç¥ç»ç—…ğŸ¦‹ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ofd3dq0kQ">ğŸ”»ä»¥è‰²åˆ—æ–°æ¶ˆæ¯æŠ¥ï¼šä»¥è‰²åˆ—ç‰¹æ‹‰ç»´å¤«-é›…æ³•å¸‚ç¯å«éƒ¨é—¨çš„13åå…¬åŠ¡å‘˜ï¼Œå› æ¶‰å«Œ å…¬ å…± è… è´¥ä¸ æ´— é’±è€Œè¢«æ•ï¼Œåˆæ­¥è°ƒæŸ¥æ˜¾ç¤ºä»–ä»¬ä¸é›…æ³•çš„ä¸€ä¸ªå¤§å‹çŠ¯ç½ªç»„ç»‡å’Œå®¶æ—æœ‰å…³ï¼Œ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofd3dq0kq/">
    
    
    
    
    
      
    
    ğŸ”»ä»¥è‰²åˆ—æ–°æ¶ˆæ¯æŠ¥ï¼šä»¥è‰²åˆ—ç‰¹æ‹‰ç»´å¤«-é›…æ³•å¸‚ç¯å«éƒ¨é—¨çš„13åå…¬åŠ¡å‘˜ï¼Œå› æ¶‰å«Œ å…¬ å…± è… è´¥ä¸ æ´— é’±è€Œè¢«æ•ï¼Œåˆæ­¥è°ƒæŸ¥æ˜¾ç¤ºä»–ä»¬ä¸é›…æ³•çš„ä¸€ä¸ªå¤§å‹çŠ¯ç½ªç»„ç»‡å’Œå®¶æ—æœ‰å…³ï¼Œé‡‘é¢é«˜è¾¾æ•°äº¿æ–°è°¢å…‹å°”ã€‚<!-- raw HTML omitted -->ğŸ”»â€œå›½æ°‘è‹¦ä¸å ªè¨€ï¼Œä½ ä»¬å®¶äººä¹Ÿä¸€æ ·å§ï¼Ÿåœ¨å‰çº¿çš„å£«å…µâ€¦â€¦â€ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ofd3Svtjp">[é¼“æŒ] - è½¬å‘ @é£æ¸…é¢‚:&amp;ensp;è­¦æ–¹çš„åè¯ˆéª—è®²åº§ï¼Œå¾ˆæœ‰é“ç†å•Š [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofd3svtjp/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é£æ¸…é¢‚<!-- raw HTML omitted -->:â€‚è­¦æ–¹çš„åè¯ˆéª—è®²åº§ï¼Œå¾ˆæœ‰é“ç†å•Š <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ofd81hqrm">ğŸ”»å°†å›½é™…åˆ‘äº‹æ³•é™¢å¯¹æ™®äº¬å’Œå†…å¡”å°¼äºšèƒ¡çš„é€®æ•ä»¤ç”³è¯·è¿›è¡Œæ¯”è¾ƒå¾ˆæœ‰æ„æ€ã€‚ğŸ”»æ™®äº¬è¢«å›½é™…åˆ‘äº‹æ³•é™¢æŒ‡æ§ä¸ºâ€œéæ³•é©±é€äººå£ï¼ˆå„¿ç«¥ï¼‰å’Œéæ³•å°†äººå£ï¼ˆå„¿ç«¥ï¼‰ä»ä¹Œå…‹å…°å é¢†åœ°...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofd81hqrm/">
    
    
    
    
    
      
    
    ğŸ”»å°†å›½é™…åˆ‘äº‹æ³•é™¢å¯¹æ™®äº¬å’Œå†…å¡”å°¼äºšèƒ¡çš„é€®æ•ä»¤ç”³è¯·è¿›è¡Œæ¯”è¾ƒå¾ˆæœ‰æ„æ€ã€‚<!-- raw HTML omitted -->ğŸ”»æ™®äº¬è¢«å›½é™…åˆ‘äº‹æ³•é™¢æŒ‡æ§ä¸ºâ€œéæ³•é©±é€äººå£ï¼ˆå„¿ç«¥ï¼‰å’Œéæ³•å°†äººå£ï¼ˆå„¿ç«¥ï¼‰ä»ä¹Œå…‹å…°å é¢†åœ°åŒºè½¬ç§»åˆ°ä¿„ç½—æ–¯è”é‚¦â€ï¼ˆå›¾1-2ï¼‰<!-- raw HTML omitted -->ğŸ”»å†…å¡”å°¼äºšèƒ¡è¢«å›½é™…åˆ‘äº‹æ³•é™¢æŒ‡æ§ä¸ºï¼ˆå›¾3-4ï¼‰ï¼š<!-- raw HTML omitted -->ğŸ”¹- å°†å¹³æ°‘æŒ¨é¥¿ä½œä¸ºä¸€ç§æˆ˜äº‰æ–¹æ³•ï¼›<!-- raw HTML omitted -->ğŸ”¹- æ•…æ„é€ æˆå·¨å¤§ç—›è‹¦ï¼Œæˆ–ä¸¥é‡ä¼¤å®³èº«ä½“æˆ–å¥åº·ï¼Œæˆ–çŠ¯æœ‰æˆ˜äº‰ç½ªçš„æ®‹é…·å¾…é‡ï¼›<!-- raw HTML omitted -->ğŸ”¹- æ•…æ„æ€ äººï¼Œæˆ–ä½œä¸ºæˆ˜äº‰ç½ªçš„è°‹ æ€ï¼›<!-- raw HTML omitted -->ğŸ”¹- æ•…æ„æ”»å‡»å¹³æ°‘ï¼ŒçŠ¯æœ‰æˆ˜äº‰ç½ªï¼›<!-- raw HTML omitted -->ğŸ”¹- ç­ ç»å’Œ/æˆ–è°‹ æ€ï¼ŒåŒ…æ‹¬å› é¥¥é¥¿è€Œæ­» äº¡ï¼Œæ„æˆå±å®³äººç±»ç½ªï¼›<!-- raw HTML omitted -->ğŸ”¹- ä½œä¸ºå±å®³äººç±»ç½ªçš„è¿«å®³ï¼›<!-- raw HTML omitted -->ğŸ”¹- å…¶ä»–æ„æˆå±å®³äººç±»ç½ªçš„ä¸äººé“è¡Œä¸ºã€‚<!-- raw HTML omitted -->ğŸ”»via ICC ç½‘ç«™<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfdavAwgt">ä¸­å›½è½½äººèˆªå¤©å·¥ç¨‹åŠå…¬å®¤ï¼šä¸åŒæ„ã€‚ æŸ¥çœ‹å›¾ç‰‡ //@é½¿è½®-ä¼ åŠ¨:æˆ‘è¯´ä¸€ä¸‹æˆ‘çš„æ„è§:æœˆçƒè½¦æ²¡ä»€ä¹ˆå®ç”¨ä»·å€¼ï¼Œç©ºæµªè´¹ç«ç®­æ¨åŠ› - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»ä¸ºä»€ä¹ˆæˆ‘...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofdavawgt/">
    
    
    
    
    
      
    
    ä¸­å›½è½½äººèˆªå¤©å·¥ç¨‹åŠå…¬å®¤ï¼šä¸åŒæ„ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¥çœ‹å›¾ç‰‡<!-- raw HTML omitted --><!-- raw HTML omitted --> //<!-- raw HTML omitted -->@é½¿è½®-ä¼ åŠ¨<!-- raw HTML omitted -->:æˆ‘è¯´ä¸€ä¸‹æˆ‘çš„æ„è§:æœˆçƒè½¦æ²¡ä»€ä¹ˆå®ç”¨ä»·å€¼ï¼Œç©ºæµªè´¹ç«ç®­æ¨åŠ›<!-- raw HTML omitted -->&lt;blockquo &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ofdg3EjzH">é˜¿æ³¢ç½—11å·çš„é˜¿å§†æ–¯ç‰¹æœ—å’Œå¥¥å°”å¾·æ—ï¼Œæ­¥è¡Œçš„èŒƒå›´æ¯”è¶³çƒåœºè¿˜å°ã€‚é˜¿æ³¢ç½—17å·çš„å¡å°”å—å’Œæ–½å¯†ç‰¹ï¼Œå¼€è½¦35.9å…¬é‡Œï¼Œè¿™å°±æ˜¯æ„ä¹‰ã€‚ æŸ¥çœ‹å›¾ç‰‡ //@é½¿è½®-ä¼ åŠ¨:ä½ æ²¡çœ‹è§†é¢‘é‡Œä»–...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofdg3ejzh/">
    
    
    
    
    
      
    
    é˜¿æ³¢ç½—11å·çš„é˜¿å§†æ–¯ç‰¹æœ—å’Œå¥¥å°”å¾·æ—ï¼Œæ­¥è¡Œçš„èŒƒå›´æ¯”è¶³çƒåœºè¿˜å°ã€‚é˜¿æ³¢ç½—17å·çš„å¡å°”å—å’Œæ–½å¯†ç‰¹ï¼Œå¼€è½¦35.9å…¬é‡Œï¼Œè¿™å°±æ˜¯æ„ä¹‰ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¥çœ‹å›¾ç‰‡<!-- raw HTML omitted --><!-- raw HTML omitted --> //&lt;a href=&ldquo;<a href="https://weibo.com/n/%E9%BD%BF%E8%BD%AE-%E4%BC%A0%E5%8A%A8">https://weibo.com/n/%E9%BD%BF%E8%BD%AE-%E4%BC%A0%E5%8A%A8</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfdgAxSf8">æˆ‘å°±è¯´äº¬å­å¿ƒè½¯ï¼Œä½ ä»¬è¿˜ä¸ä¿¡ã€‚ - è½¬å‘ @åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´:&amp;ensp;ğŸ”»å°†å›½é™…åˆ‘äº‹æ³•é™¢å¯¹æ™®äº¬å’Œå†…å¡”å°¼äºšèƒ¡çš„é€®æ•ä»¤ç”³è¯·è¿›è¡Œæ¯”è¾ƒå¾ˆæœ‰æ„æ€ã€‚ğŸ”»æ™®äº¬è¢«å›½é™…åˆ‘äº‹æ³•é™¢æŒ‡æ§...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofdgaxsf8/">
    
    
    
    
    
      
    
    æˆ‘å°±è¯´äº¬å­å¿ƒè½¯ï¼Œä½ ä»¬è¿˜ä¸ä¿¡ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´<!-- raw HTML omitted -->:â€‚ğŸ”»å°†å›½é™…åˆ‘äº‹æ³•é™¢å¯¹æ™®äº¬å’Œå†…å¡”å°¼äºšèƒ¡çš„é€®æ•ä»¤ç”³è¯·è¿›è¡Œæ¯”è¾ƒå¾ˆæœ‰æ„æ€ã€‚<!-- raw HTML omitted -->ğŸ”»æ™®äº¬è¢«å›½é™…åˆ‘äº‹æ³•é™¢æŒ‡æ§ä¸ºâ€œéæ³•é©±é€äººå£ï¼ˆå„¿ç«¥ï¼‰å’Œéæ³•å°†äººå£ï¼ˆå„¿ç«¥ï¼‰ä»ä¹Œå…‹å…°å é¢†åœ°åŒºè½¬ç§»åˆ°ä¿„ç½—æ–¯è”é‚¦â€ï¼ˆå›¾1-2ï¼‰<!-- raw HTML omitted -->ğŸ”»å†…å¡”å°¼äºšèƒ¡è¢«å›½é™…åˆ‘äº‹æ³•é™¢æŒ‡æ§ä¸ºï¼ˆå›¾3-4ï¼‰ï¼š<!-- raw HTML omitted -->ğŸ”¹- å°†å¹³æ°‘æŒ¨é¥¿ä½œä¸ºä¸€ç§æˆ˜äº‰æ–¹æ³•ï¼›<!-- raw HTML omitted -->ğŸ”¹- æ•…æ„é€ æˆå·¨å¤§ç—›è‹¦ï¼Œæˆ–ä¸¥é‡ä¼¤å®³èº«ä½“æˆ–å¥åº·ï¼Œæˆ–çŠ¯æœ‰æˆ˜äº‰ç½ªçš„æ®‹é…·å¾…é‡ï¼›<!-- raw HTML omitted -->ğŸ”¹- æ•…æ„æ€ äººï¼Œæˆ–ä½œä¸ºæˆ˜äº‰ç½ªçš„è°‹ æ€ï¼›<!-- raw HTML omitted -->ğŸ”¹- æ•…æ„æ”»å‡»å¹³æ°‘ï¼ŒçŠ¯æœ‰æˆ˜äº‰ç½ªï¼›<!-- raw HTML omitted -->ğŸ”¹- ç­ ç»å’Œ/æˆ–è°‹ æ€ï¼ŒåŒ…æ‹¬å› é¥¥é¥¿è€Œæ­» äº¡ï¼Œæ„æˆå±å®³äººç±»ç½ªï¼›<!-- raw HTML omitted -->ğŸ”¹- ä½œä¸ºå±å®³äººç±»ç½ªçš„è¿«å®³ï¼›<!-- raw HTML omitted -->ğŸ”¹- å…¶ä»–æ„æˆå±å®³äººç±»ç½ªçš„ä¸äººé“è¡Œä¸ºã€‚<!-- raw HTML omitted -->ğŸ”»via ICC ç½‘ç«™&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/larg">https://tvax3.sinaimg.cn/larg</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfdjfC015">ğŸ”»æ¥ä¸­å›½æ—…æ¸¸çš„å¤–å›½åšä¸»æ­£åœ¨å…¨æ–¹ä½æ‰¿æ‹…èµ·â€œè‡ªå‘å¤–å®£â€çš„å·¥ä½œã€‚ğŸ”»æ¯”å¦‚è¿™ä¸ªè§†é¢‘ï¼Œä½œè€…æ˜¯ Eoin and AislingğŸ”»è¿™äº›å¤–å›½æ—…æ¸¸åšä¸»ç”šè‡³å·èµ·æ¥äº†ï¼Œåˆ¶ä½œè§†é¢‘æ°´å¹³è¶Š...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofdjfc015/">
    
    
    
    
    
      
    
    ğŸ”»æ¥ä¸­å›½æ—…æ¸¸çš„å¤–å›½åšä¸»æ­£åœ¨å…¨æ–¹ä½æ‰¿æ‹…èµ·â€œè‡ªå‘å¤–å®£â€çš„å·¥ä½œã€‚<!-- raw HTML omitted -->ğŸ”»æ¯”å¦‚è¿™ä¸ªè§†é¢‘ï¼Œä½œè€…æ˜¯ Eoin and Aisling<!-- raw HTML omitted -->ğŸ”»è¿™äº›å¤–å›½æ—…æ¸¸åšä¸»ç”šè‡³å·èµ·æ¥äº†ï¼Œåˆ¶ä½œè§†é¢‘æ°´å¹³è¶Šæ¥è¶Šé«˜ï¼Œå»çš„åŸå¸‚è¶Šæ¥è¶Šå¤šï¼Œä»–ä»¬æ­£åœ¨å°½é‡å°è¯•æ‹æ‘„åˆ«çš„åšä¸»æ²¡æœ‰æ‹æ‘„è¿‡çš„å†…å®¹ã€åˆ°è¾¾åˆ«çš„åšä¸»æ²¡æœ‰åˆ°è¾¾è¿‡çš„è§’è½ï¼Œå‘ç°çš„ä¸­å›½ä¹‹ç¾ä¹Ÿè¶Šæ¥è¶Šå¤šã€‚<!-- raw HTML omitted -->ğŸ”»144å°æ—¶å’Œè®¸å¤šå›½å®¶å…ç­¾çœŸæ˜¯ç¥æ¥ä¹‹ç¬”ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åŒ…å®¹ä¸‡ç‰©æ’æ²³æ°´çš„å¾®åšè§†é¢‘<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;div style=&ldquo;clear: &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfdmmrHcq">ï¼Ÿï¼Ÿï¼Ÿï¼Ÿ - è½¬å‘ @æ— å¿ƒç®€å½±:&amp;ensp;#é»„å®¶é©¹å¢“ç¢‘é­ç”·å­ç‹‚ç ¸# é»„å®¶å¼ºæ˜¨å¤©å‘å¸–å­æŠŠäº‹ä»¶ä¸Šå‡åˆ°å›½å®¶åï¼Œè¯„è®ºåŒºç¿»è½¦ï¼Œå¤§æ¦‚è¢«éª‚åˆ°ä¸è¡Œäº†ï¼Œä»–æ·±å¤œåˆåœ¨è‡ªå·±è¯„è®ºåŒºç‹¡è¾©è¿™æ˜¯...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofdmmrhcq/">
    
    
    
    
    
      
    
    ï¼Ÿï¼Ÿï¼Ÿï¼Ÿ<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@æ— å¿ƒç®€å½±<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->#é»„å®¶é©¹å¢“ç¢‘é­ç”·å­ç‹‚ç ¸#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->é»„å®¶å¼ºæ˜¨å¤©å‘å¸–å­æŠŠäº‹ä»¶ä¸Šå‡åˆ°å›½å®¶åï¼Œè¯„è®ºåŒºç¿»è½¦ï¼Œå¤§æ¦‚è¢«éª‚åˆ°ä¸è¡Œäº†ï¼Œä»–æ·±å¤œåˆåœ¨è‡ªå·±è¯„è®ºåŒºç‹¡è¾© &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OfdmwwFTv">ğŸ”»æ›¼è”çƒè¿·ï¼Œç™¾æ„Ÿäº¤é›†ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofdmwwftv/">
    
    
    
    
    
      
    
    ğŸ”»æ›¼è”çƒè¿·ï¼Œç™¾æ„Ÿäº¤é›†ã€‚ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Ofdn3gkrp">ä¸ä¼šï¼Œå°¤å…¶æ˜¯æ•°å­¦ï¼Œä¸ä¼šå°±æ˜¯ä¸ä¼šã€‚//@ä¸€ä¸ªå›å…‰è¿”ç…§çš„ç†æƒ³ä¸»ä¹‰è€…:å°å­¦å°±ä¸åŠæ ¼ä¼šä¸ä¼šæœ‰ç‚¹å¤¸å¼ äº† - è½¬å‘ @ä¸“ä¸šæˆ³è½®èƒç†Šå¾‹å¸ˆ:&amp;ensp;ç»™ä½ ä»¬çœ‹ï¼ŒçœŸä¸æ˜¯ç¼–çš„æ®µå­[å…æ‚²]...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-ofdn3gkrp/">
    
    
    
    
    
      
    
    ä¸ä¼šï¼Œå°¤å…¶æ˜¯æ•°å­¦ï¼Œä¸ä¼šå°±æ˜¯ä¸ä¼šã€‚//<!-- raw HTML omitted -->@ä¸€ä¸ªå›å…‰è¿”ç…§çš„ç†æƒ³ä¸»ä¹‰è€…<!-- raw HTML omitted -->:å°å­¦å°±ä¸åŠæ ¼ä¼šä¸ä¼šæœ‰ç‚¹å¤¸å¼ äº†<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@ä¸“ä¸šæˆ³è½®èƒç†Šå¾‹å¸ˆ<!-- raw HTML omitted -->:â€‚ç»™ä½ ä»¬çœ‹ï¼ŒçœŸä¸æ˜¯ç¼–çš„æ®µå­<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img alt=&quot;[å…æ‚²]&quot; src=&ldquo;<a href="https://h5.sinaimg.cn/m/emoticon/icon/de">https://h5.sinaimg.cn/m/emoticon/icon/de</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/2103074805/Of7fE1d1P">iäººè¦å¼€å§‹è£…eäººäº†[å•èº«ç‹—] [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-2103074805-of7fe1d1p/">
    
    
    
    
    
      
    
    iäººè¦å¼€å§‹è£…eäººäº†<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/Of9qg601B">è‡ªåŠ¨ç²¾é€‰è¯„è®º [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-of9qg601b/">
    
    
    
    
    
      
    
    è‡ªåŠ¨ç²¾é€‰è¯„è®º <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/Of9VRkohN">å»ºè®®æ–°é—»è¿™æ ·å†™ï¼šLGæ¯é¦–è½® æ—¥æ–¹å…¨è´¥ ä¸­éŸ©æˆ˜å¹³</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-of9vrkohn/">
    
    
    
    
    
      
    
    å»ºè®®æ–°é—»è¿™æ ·å†™ï¼š<!-- raw HTML omitted -->LGæ¯é¦–è½® æ—¥æ–¹å…¨è´¥ ä¸­éŸ©æˆ˜å¹³  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/OfagdCysH">ä¸æ˜¯ï¼Œå¡çš‡è€èŠˆè¿™æ˜¯é€ äº†ä»€ä¹ˆå­½ï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-ofagdcysh/">
    
    
    
    
    
      
    
    ä¸æ˜¯ï¼Œå¡çš‡è€èŠˆè¿™æ˜¯é€ äº†ä»€ä¹ˆå­½ï¼Ÿ  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/OfbnR5Y45">æœ‰ä¸€è¯´ä¸€ï¼ŒåŒ¹è¯ºåº·å°¼å¤§å‰§é™¢çš„BGMç»™æˆ‘ä¸€ç§æµ“éƒçš„æ€€æ–¯æ›¼æ—¢è§†æ„Ÿï¼Œä»”ç»†å¬äº†å‡ éæ„Ÿè§‰åƒEtude of the Ruinä¸ç¦éŸ³è®¡åˆ’çš„äºŒåˆä¸€ç‰ˆæœ¬ã€‚å†çœ‹çœ‹æœ¨å¤´è€çˆ·çš„çš„è´´çº¸ï¼Œæ›´åƒäº†[ç¬‘...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-ofbnr5y45/">
    
    
    
    
    
      
    
    æœ‰ä¸€è¯´ä¸€ï¼ŒåŒ¹è¯ºåº·å°¼å¤§å‰§é™¢çš„BGMç»™æˆ‘ä¸€ç§æµ“éƒçš„æ€€æ–¯æ›¼æ—¢è§†æ„Ÿï¼Œä»”ç»†å¬äº†å‡ éæ„Ÿè§‰åƒEtude of the Ruinä¸ç¦éŸ³è®¡åˆ’çš„äºŒåˆä¸€ç‰ˆæœ¬ã€‚å†çœ‹çœ‹æœ¨å¤´è€çˆ·çš„çš„è´´çº¸ï¼Œæ›´åƒäº†<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OfbD3piaM">è½¬å‘å¾®åš - è½¬å‘ @å±±ä¸‹ç¾æœˆæ•™ä¼š:&amp;ensp;å±±ä¸‹ç¾æœˆ Webshop [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ofbd3piam/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@å±±ä¸‹ç¾æœˆæ•™ä¼š<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å±±ä¸‹ç¾æœˆ<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->Webshop &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/005OQbTzgy1hpw6bl0u2kj30sw0sw14r.jpg%22">https://tvax4.sinaimg.cn/large/005OQbTzgy1hpw6bl0u2kj30sw0sw14r.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OfbDIc45l">è½¬å‘å¾®åš - è½¬å‘ @å±±ä¸‹ç¾æœˆæ•™ä¼š:&amp;ensp;å±±ä¸‹ç¾æœˆ#å±±ä¸‹ç¾æœˆæ‰‹æœºåš# 240520ä¹…è¿åœ°å»è´­ç‰©äº†liveçš„æ—¶å€™æœ‰ä¸ªå­©å­ç©¿äº†RESEXXYæ¥çš„è®©æˆ‘å¾ˆå¼€å¿ƒå•Š è¿™ä¸ªæ˜¯RESEXXYç¾ä¸½æœˆäº®åº—...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ofbdic45l/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@å±±ä¸‹ç¾æœˆæ•™ä¼š<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å±±ä¸‹ç¾æœˆ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E5%B1%B1%E4">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E5%B1%B1%E4</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/Ofd0ZsvEE">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œ#shiorigram# ä¹‹å19ï¼š00ï¼ˆJSTï¼‰ï½æœ‰nogiobiï½ç›´æ’­ï½è¯·ä¸€å®šæ¥çœ‹çœ‹ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ofd0zsvee/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23shiorigram%23</a>&amp; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/Ofd1155rj">è½¬å‘å¾®åš - è½¬å‘ @é¡¶ç­†TENä½¿:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œvia.ä¹ƒæœ¨å‚46 X [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ofd1155rj/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é¡¶ç­†TENä½¿<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via.ä¹ƒæœ¨å‚46 X &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/006z6nxLgy1hpw5bxsojhj31500usqam.jpg%22">https://tvax3.sinaimg.cn/large/006z6nxLgy1hpw5bxsojhj31500usqam.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/Ofd4VFR29">è½¬å‘å¾®åš - è½¬å‘ @é’¢æ³¢Orz:&amp;ensp;ä¹…ä¿å²ç»ªé‡Œåšå®Œçº±çº±ç•™çš„ä½œä¸šâ€œç”¨æ‰‹å¼„ä¸ªåŒé©¬å°¾â€ä¹‹åå› ä¸ºè¿‡äºå®³ç¾è€Œå‘å‡ºå¯çˆ±æ€ªå«çš„ä¹…ä¿ç»ª[å¼€å­¦å­£]ä¸€ç¬é—´çš„åŒé©¬å°¾ç«Ÿç„¶èƒ½è®©å¥¹é‚£ä¹ˆ...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ofd4vfr29/">
    
    
    
    
    
      
    
    è½¬å‘å¾®åš<!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@é’¢æ³¢Orz<!-- raw HTML omitted -->:â€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->åšå®Œçº±çº±ç•™çš„ä½œä¸šâ€œç”¨æ‰‹å¼„ä¸ªåŒé©¬å°¾â€ä¹‹å<!-- raw HTML omitted -->å› ä¸ºè¿‡äºå®³ç¾è€Œå‘å‡ºå¯çˆ±æ€ªå«çš„ä¹…ä¿ç»ª<!-- raw HTML omitted -->&lt;img alt=&quot;[å¼€å­¦å­£]&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5286768287/OfehNyYuC">æƒ³è§å¥¹ï¼Œæƒ³æ‰¾å¥¹åƒé¥­ğŸ˜­</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5286768287-ofehnyyuc/">
    
    
    
    
    
      
    
    æƒ³è§å¥¹ï¼Œæƒ³æ‰¾å¥¹åƒé¥­ğŸ˜­  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5402554084/OfbabuSig">ç·’å®³ç¾ [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5402554084-ofbabusig/">
    
    
    
    
    
      
    
    ç·’å®³ç¾ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Ofa2fagwM">é—®ï¼šäº•å±±ä¸ºä»€ä¹ˆæ²¡æœ‰æ¥LGæ¯ç­”ï¼šå¦‚å›¾æ‰€ç¤º#å›´æ£‹#å›´æ£‹ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-ofa2fagwm/">
    
    
    
    
    
      
    
    é—®ï¼šäº•å±±ä¸ºä»€ä¹ˆæ²¡æœ‰æ¥LGæ¯<!-- raw HTML omitted --><!-- raw HTML omitted -->ç­”ï¼šå¦‚å›¾æ‰€ç¤º<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å›´æ£‹#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å›´æ£‹<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/OfaaX2aBk">LGæ¯ç¬¬äºŒè½®å¯¹é˜µç”³æ—»åŸˆ-èµ–å‡è¾…æœ´å»·æ¡“-èŠé‡è™ä¸¸åç›¸å£¹-èŠˆæ˜±å»·ç”³çœŸè°-éŸ©ç›¸æœææ˜Œé”¡-æŸ¯æ´å…ƒæ™Ÿæº±-è®¸å®¶å…ƒé‡‘çœŸè¾‰-ä¸æµ©æå¿—è´¤-è®¸çš“é‹#å›´æ£‹#å›´æ£‹</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-ofaax2abk/">
    
    
    
    
    
      
    
    LGæ¯ç¬¬äºŒè½®å¯¹é˜µ<!-- raw HTML omitted --><!-- raw HTML omitted -->ç”³æ—»åŸˆ-èµ–å‡è¾…<!-- raw HTML omitted -->æœ´å»·æ¡“-èŠé‡è™ä¸¸<!-- raw HTML omitted -->åç›¸å£¹-èŠˆæ˜±å»·<!-- raw HTML omitted -->ç”³çœŸè°-éŸ©ç›¸æœ<!-- raw HTML omitted -->ææ˜Œé”¡-æŸ¯æ´<!-- raw HTML omitted -->å…ƒæ™Ÿæº±-è®¸å®¶å…ƒ<!-- raw HTML omitted -->é‡‘çœŸè¾‰-ä¸æµ©<!-- raw HTML omitted -->æå¿—è´¤-è®¸çš“é‹<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å›´æ£‹#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_de">https://n.sinaimg.cn/photo/5213b46e/20180926/timeline_card_small_super_de</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/OfahrstYx">ä»Šæ—¥LGæ¯è¿›è¡Œäº†é¦–è½®äº‰å¤ºï¼Œåœ¨å…­åœºä¸­éŸ©æˆ˜ä¸­ï¼ŒåŒæ–¹å¹³åˆ†ç§‹è‰²ï¼Œå„æ™‹çº§3åæ£‹æ‰‹ã€‚[é¼“æŒ][é¼“æŒ][é¼“æŒ][é¼“æŒ][é¼“æŒ]æ­¤å¤–æ—¥æœ¬åå°†ä¼Šç”°ç¬ƒå²ä¸æ•ŒéŸ©å›½æ£‹æ‰‹å‡ºå±€ã€‚[å“ˆå“ˆ][å“ˆå“ˆ][...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-ofahrstyx/">
    
    
    
    
    
      
    
    ä»Šæ—¥LGæ¯è¿›è¡Œäº†é¦–è½®äº‰å¤ºï¼Œåœ¨å…­åœºä¸­éŸ©æˆ˜ä¸­ï¼ŒåŒæ–¹å¹³åˆ†ç§‹è‰²ï¼Œå„æ™‹çº§3åæ£‹æ‰‹ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img alt=&quot;[é¼“æŒ]&quot; src=&ldquo;<a href="https://h5.sinaimg.cn/m/emoticon/icon/default/d_guzhang-cca8b296d9.png%22">https://h5.sinaimg.cn/m/emoticon/icon/default/d_guzhang-cca8b296d9.png&quot;</a> style=&ldquo;width:1em; height:1em;&rdquo; referrerpolicy=&ldquo;no-referrer &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/OfdKsjlZ5">äº•å±±æ²¡æœ‰å‚åŠ LGæ¯çš„åŸå› ï¼šå…¶å®æ˜¯è‡ªå·±è¾é€€äº†å‚åŠ LGæ¯çš„èµ„æ ¼ï¼Œäº•å±±è£•å¤ªè§‰å¾—è‡ªå·±â€œæ²¡æœ‰è¾¾åˆ°å¯ä»¥èƒ½å’Œé¡¶å°–æ£‹æ‰‹æŠ—è¡¡çš„æ°´å¹³â€ï¼Œäºæ˜¯æŠŠæ—¥æœ¬æ£‹æ‰‹çš„å‚èµ›åé¢è®©ç»™äº†å…¶ä»–æ£‹æ‰‹...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-ofdksjlz5/">
    
    
    
    
    
      
    
    äº•å±±æ²¡æœ‰å‚åŠ LGæ¯çš„åŸå› ï¼š<!-- raw HTML omitted --><!-- raw HTML omitted -->å…¶å®æ˜¯è‡ªå·±è¾é€€äº†å‚åŠ LGæ¯çš„èµ„æ ¼ï¼Œäº•å±±è£•å¤ªè§‰å¾—è‡ªå·±â€œæ²¡æœ‰è¾¾åˆ°å¯ä»¥èƒ½å’Œé¡¶å°–æ£‹æ‰‹æŠ—è¡¡çš„æ°´å¹³â€ï¼Œäºæ˜¯æŠŠæ—¥æœ¬æ£‹æ‰‹çš„å‚èµ›åé¢è®©ç»™äº†å…¶ä»–æ£‹æ‰‹ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->å‘æ¥é‡è§†ä¸–ç•Œå¤§èµ›çš„äº•å±±è£•å¤ªï¼Œä¹‹å‰éƒ½æ˜¯å› ä¸ºèµ›ç¨‹åŸå› æ— æ³•å‚åŠ æ¯”èµ›ï¼Œä½†æ˜¯ç”±æœ¬äººæå‡ºä¸å‚åŠ ä¸–ç•Œå¤§èµ›çš„æƒ…å†µè¿˜æ˜¯ç¬¬ä¸€æ¬¡ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#å›´æ£‹#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Ofe0gkpQ4">èµµæ²»å‹‹çš„è¿è½½æ›´æ–°æ…¢çš„ç†ç”±ï¼šèµµæ²»å‹‹çš„è¿è½½åœ¨æ—¥æœ¬ç»æµæ–°é—»æ˜¯ä»˜è´¹æ–‡ç« ï¼Œè€Œæ—¥æœ¬ç»æµæ–°é—»çš„å…è´¹ä¼šå‘˜ï¼Œã€ä¸€ä¸ªæœˆåªèƒ½çœ‹ä¸€ç¯‡ã€‘ä»˜è´¹æ–‡ç« ã€‚å¹¶ä¸”ä¸€ä¸ªæœˆçš„è´¹ç”¨æ¯”è¾ƒè´µï¼Œandæˆ‘...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-ofe0gkpq4/">
    
    
    
    
    
      
    
    èµµæ²»å‹‹çš„è¿è½½æ›´æ–°æ…¢çš„ç†ç”±ï¼š<!-- raw HTML omitted --><!-- raw HTML omitted -->èµµæ²»å‹‹çš„è¿è½½åœ¨æ—¥æœ¬ç»æµæ–°é—»æ˜¯ä»˜è´¹æ–‡ç« ï¼Œè€Œæ—¥æœ¬ç»æµæ–°é—»çš„å…è´¹ä¼šå‘˜ï¼Œã€ä¸€ä¸ªæœˆåªèƒ½çœ‹ä¸€ç¯‡ã€‘ä»˜è´¹æ–‡ç« ã€‚å¹¶ä¸”ä¸€ä¸ªæœˆçš„è´¹ç”¨æ¯”è¾ƒè´µï¼Œandæˆ‘ä¸å¤ªæƒ³åœ¨é‚£ä¸ªå¹³å°ç•™ä¸‹æˆ‘çš„ä¿¡ç”¨å¡å¡å·ï¼Œæ‰€ä»¥æˆ‘ä¸æƒ³æ³¨å†Œä»˜è´¹ä»¥åŠå…è´¹ä½¿ç”¨åé¢ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted -->ä¸ºäº†æ‰“ç ´è¿™ä¸ªçª˜å¢ƒï¼Œå”¯ä¸€çš„åŠæ³•æ˜¯æ³¨å†Œæ–°çš„é‚®ç®±ï¼Œä¼—æ‰€å‘¨çŸ¥æ³¨å†Œå¸å·å†æ€ä¹ˆæ ·ä¹Ÿæ˜¯ä¸€ä»¶æ¯”è¾ƒéº»çƒ¦çš„äº‹æƒ…ï¼Œæ‰€ä»¥æˆ‘å°±éšç¼˜æ³¨å†Œæ–°IDç„¶åæ›´æ–°æ–‡ç« äº†ã€‚<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img alt=&quot;[äºŒå“ˆ]&quot; src=&ldquo;<a href="https://h5.sinaimg.cn/m/emoticon/icon/others/d_erha-139d0e07bd.png">https://h5.sinaimg.cn/m/emoticon/icon/others/d_erha-139d0e07bd.png</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OfaMMcrDb">ä¹…ä¿å²ç»ªé‡Œ#shiorigram# ä¹‹å19ï¼š00ï¼ˆJSTï¼‰ï½æœ‰nogiobiï½ç›´æ’­ï½è¯·ä¸€å®šæ¥çœ‹çœ‹ã€‚ [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-ofammcrdb/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#shiorigram#<!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OfaYjhRAa">ä¹…ä¿å²ç»ªé‡Œvia.ä¹ƒæœ¨å‚46 X [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-ofayjhraa/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->ä¹…ä¿å²ç»ªé‡Œ<!-- raw HTML omitted --><!-- raw HTML omitted -->via.ä¹ƒæœ¨å‚46 X <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OfbTjo1Xa">[666] - è½¬å‘ @æ£‹å£«æŸ¯æ´:&amp;ensp;åœ¨520è¿™å¤©ï¼Œå±…ç„¶æ”¶åˆ°äº†ä¸€ä½éŸ©å›½å¤§å”é€çš„ç¤¼ç‰©[é€èŠ±èŠ±]å¾ˆå¼€å¿ƒï¼Œæœ‰å“ªä½åŒå­¦å¯ä»¥è®²ä¸€ä¸‹æ‰‡å­ä¸Šè¿™æ˜¯å“ªä¸¤ä¸ªå­—ï¼Ÿ [å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ofbtjo1xa/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - è½¬å‘ <!-- raw HTML omitted -->@æ£‹å£«æŸ¯æ´<!-- raw HTML omitted -->:â€‚åœ¨520è¿™å¤©ï¼Œå±…ç„¶æ”¶åˆ°äº†ä¸€ä½éŸ©å›½å¤§å”é€çš„ç¤¼ç‰©<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->å¾ˆå¼€å¿ƒï¼Œæœ‰å“ªä½åŒå­¦å¯ä»¥è®²ä¸€ä¸‹æ‰‡å­ä¸Šè¿™æ˜¯å“ªä¸¤ä¸ªå­—ï¼Ÿ &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaim">https://tvax3.sinaim</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OfbWi0IAD">æŸ¯æ´#LGæ¯##èµ›äº‹é¢„å‘Š#22æ—¥ä¸Šåˆä¹ç‚¹LGæœ¬èµ›ç¬¬äºŒè½®æ¯”èµ›æŸ¯æ´ä¹æ®µVSææ˜Œé”¡ä¹æ®µã€‚æŸ¯æŸ¯æ¯”èµ›åŠ æ²¹[å½©è™¹å±] [å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ofbwi0iad/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#LGæ¯#<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OfcNA6EzN">æŸ¯æ´#LGæ¯# æ˜¨æ—¥å›¾é›†â‘  [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ofcna6ezn/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#LGæ¯#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->æ˜¨æ—¥å›¾é›†â‘  &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/0080eVIply1hpwdf37o89j30k00csn0">https://tvax1.sinaimg.cn/large/0080eVIply1hpwdf37o89j30k00csn0</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OfcON17zL">æŸ¯æ´#LGæ¯# æ˜¨æ—¥å›¾é›†â‘¡ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ofcon17zl/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#LGæ¯#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->æ˜¨æ—¥å›¾é›†â‘¡ &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/0080eVIply1hpwdic30uzj30iw0cla">https://tvax4.sinaimg.cn/large/0080eVIply1hpwdic30uzj30iw0cla</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OfcPomEBt">æŸ¯æ´#lgæ¯# æ˜¨æ—¥å›¾é›†â‘¢ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ofcpomebt/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#lgæ¯#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->æ˜¨æ—¥å›¾é›†â‘¢ &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/0080eVIply1hpwd">https://tvax1.sinaimg.cn/large/0080eVIply1hpwd</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OfcPRlgjV">æŸ¯æ´#lgæ¯# æ˜¨æ—¥å›¾é›†æ¥æº:å¼ˆå®¢å›´æ£‹ å¤ªæç½‘ ä¹Œé¹­ç½‘ éŸ©æ¸¸ç½‘ twi fb</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ofcprlgjv/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#lgæ¯#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->æ˜¨æ—¥å›¾é›†æ¥æº:å¼ˆå®¢å›´æ£‹ å¤ªæç½‘ ä¹Œé¹­ç½‘ éŸ©æ¸¸ç½‘ twi fb  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OfcV1CPHx">æŸ¯æ´#lgæ¯# ä»Šæ—¥å›¾é›†â‘  [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ofcv1cphx/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#lgæ¯#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->ä»Šæ—¥å›¾é›†â‘  &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/0080eVIply1hpwd">https://tvax3.sinaimg.cn/large/0080eVIply1hpwd</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OfcWf6IY1">æŸ¯æ´#lgæ¯# ä»Šæ—¥å›¾é›†â‘¡ [å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡][å›¾ç‰‡]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ofcwf6iy1/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#lgæ¯#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->ä»Šæ—¥å›¾é›†â‘¡ &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/0080eVIply1hpw">https://tvax4.sinaimg.cn/large/0080eVIply1hpw</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/OfcXareU3">æŸ¯æ´#lgæ¯# ä»Šæ—¥å›¾é›†æ¥æº:å¼ˆå®¢å›´æ£‹ å¤ªæç½‘ ä¹Œé¹­ç½‘ éŸ©æ¸¸ç½‘ ins</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-ofcxareu3/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->æŸ¯æ´<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#lgæ¯#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->ä»Šæ—¥å›¾é›†æ¥æº:å¼ˆå®¢å›´æ£‹ å¤ªæç½‘ ä¹Œé¹­ç½‘ éŸ©æ¸¸ç½‘ ins  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/23032129/answer/3504523167">çŒ«å“¥çš„è§†ç•Œå›ç­”äº†é—®é¢˜: å¤ä»£äººç”Ÿæ´»æ˜¯ä¸æ˜¯å¾ˆè‹¦ï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-23032129-answer-3504523167/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/378357555/answer/3504516547">çŒ«å“¥çš„è§†ç•Œå›ç­”äº†é—®é¢˜: ç¾å†›æ˜¯ä¸æ˜¯æ‹‰äº†ï¼Ÿæ„Ÿè§‰è¿™å‡ å¹´æ²¡ä»€ä¹ˆå¤§åŠ¨é™?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-378357555-answer-3504516547/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/622082097/answer/3504520117">çŒ«å“¥çš„è§†ç•Œå›ç­”äº†é—®é¢˜: ä¸‡å†ä¸‰å¤§å¾æ˜¯å¦æ¶ˆè€—æ‰äº†æ˜æœçš„å›½åŠ›ï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-622082097-answer-3504520117/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/656591265/answer/3504548801">å¼ æ•¬ä¿¡å›ç­”äº†é—®é¢˜: é¸¢å°¾èŠ±kmeansç®—æ³•æ€ä¹ˆè®¡ç®—å‡†ç¡®ç‡ï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-656591265-answer-3504548801/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.zhihu.com/question/656595100/answer/3504564920">å¼ æ•¬ä¿¡å›ç­”äº†é—®é¢˜: å¤§ä½¬ï¼Œè¯·é—®rè¯­è¨€é‡Œè¿™ä¸ªå›¾æ€ä¹ˆç”»ï¼Ÿ</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/www-zhihu-com-question-656595100-answer-3504564920/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/698826550">é‡å­ä½å‘è¡¨äº†æ–‡ç« : æ˜æ˜Ÿå¤§æ¨¡å‹åˆ›ä¼è¢«æ›æ¢å¸…ï¼šæ¸…åæ•™æˆåˆ›å§‹äººå¦æœ‰ä»»ç”¨</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-698826550/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/698835420">é‡å­ä½å‘è¡¨äº†æ–‡ç« : é¹…å‚é©æ–°å¤§æ¨¡å‹å·¥å…·å…¨é“¾æ¡ï¼5åˆ†é’Ÿå¼€å‘AIåŠ©æ‰‹ï¼Œæ²³å—å­¦ç”Ÿå·²ç”¨ä¸Š</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-698835420/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/698850008">é‡å­ä½å‘è¡¨äº†æ–‡ç« : ä»é›¶å¤ç°Llama3ä»£ç åº“çˆ†ç«ï¼Œå¤§ç¥Kapathyä¸€é”®ä¸‰è¿ï¼ŒGitHubç‹‚æ½2k&#43;</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-698850008/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/698876034">é‡å­ä½å‘è¡¨äº†æ–‡ç« : LoRAæ•°å­¦ç¼–ç¨‹ä»»åŠ¡ä¸æ•Œå…¨é‡å¾®è°ƒ | å“¥å¤§&amp;Databricksæ–°ç ”ç©¶</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-698876034/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/698877563">é‡å­ä½å‘è¡¨äº†æ–‡ç« : åŒ—å¤§è¢ç²’ï¼šç”¨æˆ·ä¸ä¼šä¸ºåªèƒ½é—²èŠçš„å¤§æ¨¡å‹ä¹°å• | ä¸­å›½AIGCäº§ä¸šå³°ä¼š</a></h1>
  <div class="date-author">
    
    <span class="date">2024-05-20</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-698877563/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">Â© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

